EVAX | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-5.62%

1 Month

14.49%

3 Months

0.50%

6 Months

-34.26%

1 Year

144.24%

2 Year

-6.06%

Key data

Stock price

$4.03

P/E Ratio

0.00

DAY RANGE

$3.98 - $4.27

EPS

N/A

52 WEEK RANGE

$1.42 - $12.15

52 WEEK CHANGE

$144.24

MARKET CAP

17.007 M

YIELD

N/A

SHARES OUTSTANDING

5.576 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

01-14-2025

NEXT EARNINGS DATE

05-27-2025

BETA

1.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$52,120

AVERAGE 30 VOLUME

$32,803

Company detail

CEO: Per Norlén
Region: US
Website: evaxion-biotech.com
Employees: 60
IPO year: 2021

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Evaxion Biotech A/S identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma.

EVAX - Evaxion Biotech A/S